Udaipur, June 5: In a historic achievement that underscores India’s growing dominance in global healthcare innovation, SS Innovations International, the creators of the indigenously developed SSI Mantra surgical robotic system, rang the opening bell at the Nasdaq MarketSite in New York today. The company’s shares are now officially listed on Nasdaq under the ticker symbol ‘SSII’, marking a significant milestone not just for the company but for Indian medtech on the world stage.
A Defining Leap for Indian Medical Technology
The bell-ringing ceremony was led by Dr. Sudhir Srivastava, Founder, Chairman, and CEO of SS Innovations International, accompanied by members of the company’s executive team, board of directors, and distinguished guests. The occasion celebrated the company’s uplisting to Nasdaq in April 2025 and highlighted its journey as a pioneer in surgical robotics made in India.
Dr. Srivastava, a global leader in robotic cardiac surgery, shared his excitement:
“Today’s bell-ringing ceremony marks a proud moment not only for SS Innovations but for India. Our flagship product, the SSI Mantra, is an advanced, affordable, and world-class surgical robotic system built entirely in India. It’s been used in over 4,000 surgeries across more than 100 procedures — with zero complications or mortalities — proving its unmatched precision, safety, and potential to revolutionize surgery worldwide.”
SSI Mantra: From India to the World
SS Innovations International has made extraordinary strides with its patented and clinically validated SSI Mantra Surgical Robotic System. To date, the technology has been installed at 80 hospitals across 75 locations in India, and is now being adopted internationally in countries such as Nepal, Sri Lanka, the Philippines, Ecuador, Colombia, Guatemala, Indonesia, and Ukraine.
The company’s global vision includes expansion into the European Union and the United States, further positioning India as a rising powerhouse in medical robotics. The SSI Mantra aims to bridge the accessibility gap in robotic surgery by providing cost-effective, high-quality surgical care — a mission aligned with global healthcare goals.
India’s Medtech Moment
SS Innovations’ Nasdaq debut not only marks a commercial success but also a symbolic shift — it signals India’s emergence as a credible leader in high-precision, affordable healthcare technologies. At a time when advanced medical robotics remain out of reach for many patients worldwide, the SSI Mantra offers a bold and inclusive solution.
As Dr. Srivastava aptly put it,
“Our mission is to democratize robotic surgery — making it available to patients across all geographies and income levels, with India leading this global movement.”
This milestone reaffirms India’s role in shaping the future of healthcare innovation, making cutting-edge technologies accessible to millions while fostering global confidence in indigenous innovation.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
